Introduction to ProLung

The ProLung Test™: Making the Difference in Time

The ProLung Test uses precision proprietary volume-averaging bioconductance technology to measure the difference in conductivity between malignant and benign lung tissue. The data is analyzed to produce a personalized and predictive score indicating the likelihood that a particular lesion in the lungs is malignant.

There is a severe unmet clinical need to reduce the time required to determine malignancy in patients diagnosed with Indeterminate Pulmonary Nodules (IPNs). Patients with IPNs may wait months, or even years, receiving multiple CT scans to identify malignancy in the lungs, when present. This wait often proves fatal.

In 2015, the US Preventative Services Task Force and Centers for Medicare and Medicaid Services (CMS) added annual screening for lung cancer with low dose computed tomography (LDCT) as a covered Medicare benefit for patients meeting certain criteria. This new Medicare benefit will facilitate the identification of an additional 22 million patients with pulmonary lesions of indeterminate significance.